Background:Benvitimod cream,a novel synthetic small molecule,was effective in treating mild-to-moderate plaque psoriasis.We conducted a phase III clinical trial to assess the efficacy and safety of benvitimod cream in...Background:Benvitimod cream,a novel synthetic small molecule,was effective in treating mild-to-moderate plaque psoriasis.We conducted a phase III clinical trial to assess the efficacy and safety of benvitimod cream in patients with mild-to-moderate plaque psoriasis.Methods:We randomly assigned 686 patients(2:1:1)to receive 1%benvitimod cream,0.005%calcipotriol ointment or placebo twice a day for 12 weeks.The primary efficacy end points were the percentage of patients with a 75%or greater reduction from baseline in the psoriasis area and severity index(PASI 75)score and with a score of 0 or 1 in static physician’s global assessment(sPGA)at week 12.Results:The results showed that 50.4%of patients in the benvitimod group achieved PASI 75,which was significantly higher than that in the calcipotriol(38.5%,P<0.05)and placebo(13.9%,P<0.05)groups.The proportion of patients achieving an sPGA score 0 or 1 was 66.3%in the benvitimod group and 63.9%in the calcipotriol group,which were both significantly higher than that in the placebo group(34%,P<0.05).In the long-term follow-up study,50.8%of patients experienced recurrence.After retreatment with 1%benvitimod,73.3%of patients achieved an sPGA score of 0 or 1 again at week 52.Adverse events included application site irritation,follicular papules,and contact dermatitis.No systemic adverse reactions were reported.Conclusion:During this 12-week study,benvitimod cream was demonstrated with high effectiveness and safety in patients with mild-to-moderate plaque psoriasis.展开更多
Atopic dermatitis(AD)and psoriasis are common chronic and relapsing inflammatory skin diseases mainly mediated by T cells.Type 2 and 17 inflammations are essential in the pathogenesis of AD and psoriasis,respectively....Atopic dermatitis(AD)and psoriasis are common chronic and relapsing inflammatory skin diseases mainly mediated by T cells.Type 2 and 17 inflammations are essential in the pathogenesis of AD and psoriasis,respectively.Clinical evidence suggests that benvitimod,a natural metabolite produced by bacterial symbionts,plays a therapeutic role in the development and progression of both AD and psoriasis.Mechanistically,the two most potent interactions with benvitimod are observed in the aryl hydrocarbon receptor(AhR)and nuclear factor-erythroid 2-related factor-2(Nrf2)pathways.However,it remains largely unknown how is the local interplay among benvitimod,AhR,and Nrf2,and how the epithelial microenvironment contributes to the complex inflammatory context that results in the treatment of AD and psoriasis.In the present study,the modulatory effects of benvitimod on treating AD and psoriasis.展开更多
目的观察苯烯莫德对实验性银屑病的影响。方法体外培养永生化人角质生成细胞Ha Ca T,用MTT法测试苯烯莫德的抑制率,免疫组化法观察角蛋白19(CK19)的表达。体内试验以维A酸乳膏为阳性对照,观察0.5%、1%、2%苯烯莫德药效(苯烯莫德低、中...目的观察苯烯莫德对实验性银屑病的影响。方法体外培养永生化人角质生成细胞Ha Ca T,用MTT法测试苯烯莫德的抑制率,免疫组化法观察角蛋白19(CK19)的表达。体内试验以维A酸乳膏为阳性对照,观察0.5%、1%、2%苯烯莫德药效(苯烯莫德低、中、高剂量组),并设阴性对照组。雌性性成熟小鼠60只,雌二醇诱导小鼠动情期阴道上皮有丝分裂模型成功后随机分组,从阴道注入样品(50μL),检测阴道组织有丝分裂指数。60只小鼠随机分组,给药前各组动物均用尼龙刷轻刷尾根0.5 cm处100次制作小鼠尾部颗粒层鳞片数模型,然后在同一部位涂抹给药(100μL),计数给药部位每100个鳞片中有颗粒层的鳞片数。80只豚鼠随机分组,普萘洛尔诱导豚鼠耳背部银屑病样模型成功后涂抹药剂(约200μL)于豚鼠耳背,取给药部位皮肤显微测表皮厚度。结果体外试验显示苯烯莫德对Ha Ca T细胞的IC50为28.5μg·m L-1,Ha Ca T细胞在20μg·m L-1苯烯莫德中培养,有大量CK19生成。苯烯莫德能抑制小鼠阴道上皮细胞的有丝分裂,苯烯莫德各剂量组有丝分裂细胞指数低于赋形剂组(P<0.05或P<0.01),苯烯莫德中、高剂量组低于苯烯莫德低剂量组(P<0.05,P<0.01)。苯烯莫德处理后能增加含颗粒层的鳞片数,苯烯莫德各剂量组小鼠尾部有颗粒层的鳞片比率高于赋形剂组(P<0.05或P<0.01),苯烯莫德中、高剂量组高于苯烯莫德低剂量组(P<0.05,P<0.01)。普萘洛尔诱导的豚鼠耳背部表皮的厚度增加能够被苯烯莫德抑制,苯烯莫德各剂量组表皮厚度薄于赋形剂组(P<0.05或P<0.01),苯烯莫德高剂量组薄于苯烯莫德低剂量组(P<0.05)。结论苯烯莫德具有明显治疗实验性银屑病的作用,具有开发前景。展开更多
基金Beijing Wenfeng Tianji Pharma Ltd.and the grant from National Science and Technology Major Project of the Ministry of Science and Technology of China(No.2011ZX09101-006-02)。
文摘Background:Benvitimod cream,a novel synthetic small molecule,was effective in treating mild-to-moderate plaque psoriasis.We conducted a phase III clinical trial to assess the efficacy and safety of benvitimod cream in patients with mild-to-moderate plaque psoriasis.Methods:We randomly assigned 686 patients(2:1:1)to receive 1%benvitimod cream,0.005%calcipotriol ointment or placebo twice a day for 12 weeks.The primary efficacy end points were the percentage of patients with a 75%or greater reduction from baseline in the psoriasis area and severity index(PASI 75)score and with a score of 0 or 1 in static physician’s global assessment(sPGA)at week 12.Results:The results showed that 50.4%of patients in the benvitimod group achieved PASI 75,which was significantly higher than that in the calcipotriol(38.5%,P<0.05)and placebo(13.9%,P<0.05)groups.The proportion of patients achieving an sPGA score 0 or 1 was 66.3%in the benvitimod group and 63.9%in the calcipotriol group,which were both significantly higher than that in the placebo group(34%,P<0.05).In the long-term follow-up study,50.8%of patients experienced recurrence.After retreatment with 1%benvitimod,73.3%of patients achieved an sPGA score of 0 or 1 again at week 52.Adverse events included application site irritation,follicular papules,and contact dermatitis.No systemic adverse reactions were reported.Conclusion:During this 12-week study,benvitimod cream was demonstrated with high effectiveness and safety in patients with mild-to-moderate plaque psoriasis.
文摘Atopic dermatitis(AD)and psoriasis are common chronic and relapsing inflammatory skin diseases mainly mediated by T cells.Type 2 and 17 inflammations are essential in the pathogenesis of AD and psoriasis,respectively.Clinical evidence suggests that benvitimod,a natural metabolite produced by bacterial symbionts,plays a therapeutic role in the development and progression of both AD and psoriasis.Mechanistically,the two most potent interactions with benvitimod are observed in the aryl hydrocarbon receptor(AhR)and nuclear factor-erythroid 2-related factor-2(Nrf2)pathways.However,it remains largely unknown how is the local interplay among benvitimod,AhR,and Nrf2,and how the epithelial microenvironment contributes to the complex inflammatory context that results in the treatment of AD and psoriasis.In the present study,the modulatory effects of benvitimod on treating AD and psoriasis.
文摘目的观察苯烯莫德对实验性银屑病的影响。方法体外培养永生化人角质生成细胞Ha Ca T,用MTT法测试苯烯莫德的抑制率,免疫组化法观察角蛋白19(CK19)的表达。体内试验以维A酸乳膏为阳性对照,观察0.5%、1%、2%苯烯莫德药效(苯烯莫德低、中、高剂量组),并设阴性对照组。雌性性成熟小鼠60只,雌二醇诱导小鼠动情期阴道上皮有丝分裂模型成功后随机分组,从阴道注入样品(50μL),检测阴道组织有丝分裂指数。60只小鼠随机分组,给药前各组动物均用尼龙刷轻刷尾根0.5 cm处100次制作小鼠尾部颗粒层鳞片数模型,然后在同一部位涂抹给药(100μL),计数给药部位每100个鳞片中有颗粒层的鳞片数。80只豚鼠随机分组,普萘洛尔诱导豚鼠耳背部银屑病样模型成功后涂抹药剂(约200μL)于豚鼠耳背,取给药部位皮肤显微测表皮厚度。结果体外试验显示苯烯莫德对Ha Ca T细胞的IC50为28.5μg·m L-1,Ha Ca T细胞在20μg·m L-1苯烯莫德中培养,有大量CK19生成。苯烯莫德能抑制小鼠阴道上皮细胞的有丝分裂,苯烯莫德各剂量组有丝分裂细胞指数低于赋形剂组(P<0.05或P<0.01),苯烯莫德中、高剂量组低于苯烯莫德低剂量组(P<0.05,P<0.01)。苯烯莫德处理后能增加含颗粒层的鳞片数,苯烯莫德各剂量组小鼠尾部有颗粒层的鳞片比率高于赋形剂组(P<0.05或P<0.01),苯烯莫德中、高剂量组高于苯烯莫德低剂量组(P<0.05,P<0.01)。普萘洛尔诱导的豚鼠耳背部表皮的厚度增加能够被苯烯莫德抑制,苯烯莫德各剂量组表皮厚度薄于赋形剂组(P<0.05或P<0.01),苯烯莫德高剂量组薄于苯烯莫德低剂量组(P<0.05)。结论苯烯莫德具有明显治疗实验性银屑病的作用,具有开发前景。
